22.01.2018 03:21:14

WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln

(RTTNews) - Sanofi SA (SNYNF, SNY) is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. (BIVV) for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product, the Wall Street Journal reported citing people familiar with the matter

A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share. The price would represent a 63% premium to where Bioverativ closed trading Friday. It is possible the talks could fall apart before a deal is reached, the Journal reported.

Analysen zu Sanofi S.A.mehr Analysen

20.02.25 Sanofi Outperform Bernstein Research
14.02.25 Sanofi Neutral JP Morgan Chase & Co.
13.02.25 Sanofi Buy UBS AG
03.02.25 Sanofi Buy UBS AG
31.01.25 Sanofi Kaufen DZ BANK
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Biogen Inc 134,20 -0,07% Biogen Inc
Sanofi S.A. 102,80 -1,32% Sanofi S.A.
Sanofi S.A. (spons. ADRs) 51,00 0,00% Sanofi S.A. (spons. ADRs)